Literature DB >> 12093180

Structural features of envelope proteins on hepatitis C virus-like particles as determined by anti-envelope monoclonal antibodies and CD81 binding.

Miriam Triyatni1, John Vergalla, Anthony R Davis, Kenneth G Hadlock, Steven K H Foung, T Jake Liang.   

Abstract

The envelope glycoprotein E2 of hepatitis C virus (HCV) is a major component of the viral envelope. Knowledge of its topologic features and antigenic determinants in virions is crucial in understanding the viral binding sites to cellular receptor(s) and the induction of neutralizing antibodies. The lack of a robust cell culture system for virus propagation has hampered the characterization of E2 presented on the virion. Here we report the structural features of hepatitis C virus-like particles (HCV-LPs) of the 1a and 1b genotypes as determined by various mouse and human monoclonal anti-envelope antibodies. Our results show that the E2 protein of HCV-LPs reacts with human monoclonal antibodies recognizing conformational determinants. Monoclonal antibodies (mAbs) specific for the hypervariable region 1 (HVR-1) sequence reacted strongly with HCV-LPs, suggesting that the HVR-1 is exposed on the viral surface. Several mAbs recognized both HCV-LPs with equally high affinity, indicating that the corresponding epitopes [amino acids (aa) 192-217 of E1 and aa 412-423, aa 522-531, and aa 640-653 of E2] are conserved in both genotypes and exposed on the surface of the HCV-LP. The E2 and E1/E2 dimers of 1a bound strongly to the recombinant large extracellular loop (LEL) of CD81 (CD81-LEL) of human and African green monkey, while the HCV-LP of 1a bound weakly to human CD81-LEL. E1/E2 dimers and the HCV-LPs of 1b did not bind CD81-LEL, consistent with the notion that CD81 recognition by E2 is strain-specific and does not correlate with permissiveness of infection. A model of the topology and exposed antigenic determinants of the envelope proteins of HCV is proposed. (c) 2002 Elsevier Science (USA).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12093180     DOI: 10.1006/viro.2002.1463

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  32 in total

1.  Conformational changes in the herpes simplex virus ICP8 DNA-binding protein coincident with assembly in viral replication structures.

Authors:  Susan L Uprichard; David M Knipe
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

2.  Multimeric HCV E2 protein obtained from Pichia pastoris cells induces a strong immune response in mice.

Authors:  Gillian Martínez-Donato; Yanelis Capdesuñer; Nelson Acosta-Rivero; Armando Rodríguez; Juan Morales-Grillo; Eduardo Martínez; Marleny González; Julio C Alvarez-Obregon; Santiago Dueñas-Carrera
Journal:  Mol Biotechnol       Date:  2007-03       Impact factor: 2.695

Review 3.  Capitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine design.

Authors:  Leopold Kong; Kelli N Jackson; Ian A Wilson; Mansun Law
Journal:  Curr Opin Virol       Date:  2015-04-29       Impact factor: 7.090

4.  CD81-dependent binding of hepatitis C virus E1E2 heterodimers.

Authors:  Laurence Cocquerel; Chiung-Chi Kuo; Jean Dubuisson; Shoshana Levy
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

5.  Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein.

Authors:  Ania Owsianka; Alexander W Tarr; Vicky S Juttla; Dimitri Lavillette; Birke Bartosch; François-Loïc Cosset; Jonathan K Ball; Arvind H Patel
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

Review 6.  Neutralizing antibodies in hepatitis C virus infection.

Authors:  Mirjam-B Zeisel; Samira Fafi-Kremer; Isabel Fofana; Heidi Barth; Francoise Stoll-Keller; Michel Doffoel; Thomas-F Baumert
Journal:  World J Gastroenterol       Date:  2007-09-28       Impact factor: 5.742

7.  Strategies to reduce hepatitis C virus recurrence after liver transplantation.

Authors:  Ruben Ciria; María Pleguezuelo; Shirin Elizabeth Khorsandi; Diego Davila; Abid Suddle; Hector Vilca-Melendez; Sebastian Rufian; Manuel de la Mata; Javier Briceño; Pedro López Cillero; Nigel Heaton
Journal:  World J Hepatol       Date:  2013-05-27

8.  Human monoclonal antibody to hepatitis C virus E1 glycoprotein that blocks virus attachment and viral infectivity.

Authors:  Zhen-Yong Keck; Vicky M H Sung; Susan Perkins; Judy Rowe; Sudhir Paul; T Jake Liang; Michael M C Lai; Steven K H Foung
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

9.  Immunization with hepatitis C virus-like particles induces humoral and cellular immune responses in nonhuman primates.

Authors:  Sook-Hyang Jeong; Ming Qiao; Michelina Nascimbeni; Zongyi Hu; Barbara Rehermann; Krishna Murthy; T Jake Liang
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

10.  Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity.

Authors:  Pei Zhang; Lilin Zhong; Evi Budo Struble; Hisayoshi Watanabe; Alla Kachko; Kathleen Mihalik; Maria Luisa Virata; Harvey J Alter; Stephen Feinstone; Marian Major
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-20       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.